Know more... - Pancreatic Cancer India

More documents

Recommendations

Info

Dr Bhawna Sirohi’s CV 5. Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Pandha, H., Bhagwati, N., Horton, C., Singhal, S., Mehta, J. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplantation 2000; 25, (5) 533-539 6. Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Sirohi, B., Millar, B., Shepherd, V., Saso, R., Rowland, A., Long, S., Cabral, S., Horton, C., Mehta, J. Comparison of marrow and blood cell yields from the same donors in a doubleblind, randomized study of allogeneic marrow versus blood stem cell transplantation. Bone Marrow Transplantation 2000 25: (5) 501-505. 7. Kulkarni, S., Powles, R., Treleaven, J., Riley, U., Singhal, S., Horton, C., Sirohi, B., Bhagwati, N., Meller, S., Saso, R., Mehta, J. Chronic GVHD is associated with long-term risk of pneumococcal infections in bone marrow transplant patients. Blood, 2000, 95:(12) p3683-86. 8. Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Horton, C., Sirohi, B., Bhagwati, N., Tait, D., Saso, R., Killick, Pinkerton, R., Atra, A., Meller, S., Mehta, J. Melphalan/TBI is not <strong>more</strong> carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years. Bone Marrow Transplant 2000 25,(4) 365-370. 9. Powles, R., Sirohi, B., Kulkarni, S., Bhagwati, N., Saso, R., Raje, J., Horton, C., Singhal, S., Mehta, J., Treleaven, J. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - A phase I/II feasibility and tolerance study of 17 patients. Bone Marrow Transplant 2000 25: (9) 949-956. 10. Powles, R., Mehta, J., Kulkarni, S., Treleaven, J., Millar, B., Shepherd, V., Rowland, A., Sirohi, B., Tait, D., Horton, C., Long, S., Singhal, S. Allogeneic blood and marrow stem cell transplantation in haematologic malignant disease: a randomised trial. Lancet 2000, 355: 1231-1237 11. Singhal, S., Powles, R., Treleaven, J., Kulkarni, S., Sirohi, B., Horton, C., Millar, J., Shepherd, V., Tait, D., Saso, R., Rowland, A., Long, S., Mehta, J. A low CD34+ cell dose results in higher mortality and poorer survival or marrow stem cell transplantation from HLA-identical siblings: Should CD34+ cells/kg be considered the maximum threshold? Bone Marrow Transplantation, 2000 Sep, 36(5) p489-96. 12. Sirohi B, Powles R L, Kulkani S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, and Treleaven J. Glomerular filtration rate prior to high dose melphalan 200 mg/m 2 as a surrogate marker or outcome in patients with myeloma. British Journal of <strong>Cancer</strong> 2001; 85 (3):325-332. 13. Sirohi, B., and Powles, R., : High-Dose Therapy in Patients with Multiple Myeloma: Oncology Spectrums,2002;2 (2): Pages 86-95. 14. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J, Horton C, Treleaven J. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplantation, 2001; 28:29-37. 15. Sirohi B, Kulkarni S, Powles R. Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden Experience. Seminars in Hematology. Vol. 38. July 2001, page 209-18. 26
Dr Bhawna Sirohi’s CV 16. Sirohi B and Powles R. International Myeloma Grand Round. The Lancet Oncology, Vol 2 (9) 2001: 571-579. 17. Sirohi B, Powles R, Mehta J, Treleaven J, Raje N, Kulkarni S, Rudin C, Bhagwati N, Horton C, Saso R, Singhal S, Parikh P. The Implication of compromised renal function at presentation in myeloma. Medical Oncology: vol 18(1) 2001: 39-50 18. Singhal, S., Powles, R., Henslee-Downey, P.J., Chiang, K.Y., Treleaven, J., Godder, K., Kulkarni, S., van Rhee, S., Sirohi, B., Pinkerton, C.R., Meller, S., Mehta, J. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refactory acute leukaemia. Bone Marrow Transplantation, 2002; 29(4): 291-295. 19. Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Tait, D., Singhal, S., Mehta, J. The role of post-transplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukaemia. Blood, 2002, 100(5): 1641-1647. 20. Powles, R., Sirohi, B. Kulkarni, S., Treleaven, J., Rudin, C., Sankpal, S., Goyal, S., Horton, C., Millar, B., Saso, R., Singhal, S., Mehta, J. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone Marrow Transplantation, 2002, 30, 479-484. 21. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from highdose melphalan and autotransplantation in myeloma. Bone Marrow Transplantation 2002; 30 (10): 673-9. 22. Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Tait, D., Singhal, S. Does donor-recipient ABO-incompatible protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukaemia? Bone Marrow Transplantation 2002; 29 (10): 853-9. 23. Elnenaei MO, Gruszka-Westwood AM, A’Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma; the relevances of TP53, MDM2, and CDKN2A. Haematologica 2003;88: 529-537. 24. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, Atra A, Ortin M, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic haematopoietic stem cell transplantation : activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplantation 2003;32:165-70. 25. Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukaemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes? Bone Marrow Transplantation 2003;32:157-64. 26. Singhal S, Henslee-Downey PJ, Polwes R, Chiang KY, godder K, Treleaven J, Kulkarni S, Van Rhee F, Sirohi B, Pinkerton CR, Meller S, Jovanovic B, Mehta J. Haploidentical vs autologous haematopoietic stem cell transplantation in patients with acute leukaemia beyond first remission. Bone Marrow Transplantation 2003;31:889-95. 27. Sirohi B, Powles R, Treleaven J, Rudin C, Kulkarni S, Frassoni F, Bacigalupo A, Singhal S, Labopin M, Michallet M, Blaise D, Reiffers J, Meloni G, Rio B, Horton C, Mehta J. Reassessing autotransplantation for acute myeloid 27
Page 1 and 2: Dr Bhawna Sirohi’s CV CURRICULUM
Page 3 and 4: Dr Bhawna Sirohi’s CV I joined Gu
Page 5 and 6: Dr Bhawna Sirohi’s CV July 1992-A
Page 7 and 8: Dr Bhawna Sirohi’s CV Editor, Art
Page 9 and 10: Dr Bhawna Sirohi’s CV 1999- 2007:
Page 11 and 12: Dr Bhawna Sirohi’s CV trusts in U
Page 13 and 14: Dr Bhawna Sirohi’s CV 18. Results
Page 15 and 16: Dr Bhawna Sirohi’s CV High Incide
Page 17 and 18: Dr Bhawna Sirohi’s CV 48. Implica
Page 19 and 20: Dr Bhawna Sirohi’s CV 2048 A rand
Page 21 and 22: Dr Bhawna Sirohi’s CV 5. Principl
Page 23 and 24: Dr Bhawna Sirohi’s CV 56. Role of
Page 25: Dr Bhawna Sirohi’s CV 106. Panel
Page 29 and 30: Dr Bhawna Sirohi’s CV A, Niederwi
Page 31 and 32: Dr Bhawna Sirohi’s CV 61. Sirohi

Know more... - Pancreatic Cancer India

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?